Impressive clinical activity was demonstrated in a phase I trial of an oral ATP- competitive TKI of ALK and c-MET, crizotinib (PF-02341066), in patients with advanced NSCLC and whose tumors harbored ALK rearrangement by FISH analysis [87]. This evidence concerns the gene MET and non-small cell lung carcinoma.